Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Moore, K.P., Zhu, H., Rajapakse, H.A., McGaughey, G.B., Colussi, D., Price, E.A., Sankaranarayanan, S., Simon, A.J., Pudvah, N.T., Hochman, J.H., Allison, T., Munshi, S.K., Graham, S.L., Vacca, J.P., Nantermet, P.G.(2007) Bioorg Med Chem Lett 17: 5831-5835
- PubMed: 17827011 
- DOI: https://doi.org/10.1016/j.bmcl.2007.08.040
- Primary Citation of Related Structures:  
2PH8, 2QZK - PubMed Abstract: 
This letter describes replacements for the P3 amide moiety present in previously reported tertiary carbinamine macrolactones. Although P-gp efflux issues associated with these amide-macrolactones were solved and full brain penetration was measured in one case, potency was compromised in the process.
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 4, West Point, PA 19486, USA. keith_moore2@merck.com